Qiagen (QGEN) Q2 2025 earnings summary

Executive summary

• Net sales for Q2 2025 reached $534 million, up 7% year-over-year and 6% at CER, exceeding outlook; adjusted diluted EPS was $0.60 ($0.62 CER), with a 29.9% adjusted operating margin, up 1.5 points from Q2 2024.

• Diagnostic solutions led growth with 11% CER, driven by QIAstat-Dx (+41% CER) and QuantiFERON (+11% CER); core sales also rose 6% CER.

• Strategic investments, efficiency gains, and portfolio strength supported profitability, offsetting new tariffs and supporting reinvestment in key initiatives.

• Over $350 million returned to shareholders in 2025 via share repurchases and first annual dividend; $650 million returned since 2024.

Financial highlights

• Adjusted operating income margin improved to 29.9% of sales, up 1.5 percentage points from Q2 2024; adjusted operating income rose 13% to $160 million.

• Adjusted diluted EPS was $0.60 ($0.62 CER), ahead of targets and up 9% year-over-year.

• Net cash from operating activities was $301 million in H1 2025, unchanged from H1 2024.

• Free cash flow was $217 million, slightly below $225 million in H1 2024 due to higher capital expenditures and digital investments.

• Gross profit margin for Q2 2025 was 62.7%; adjusted gross profit margin was 66.7%.

Outlook and guidance

• FY 2025 net sales outlook raised to 4%-5% CER growth (core 5%-6% CER); adjusted EPS target reaffirmed at $2.35 CER.

• Q3 2025 targets: at least 4% CER net sales growth, 5% CER core growth, and adjusted EPS of at least $0.58 CER.

• Adjusted operating income margin target for FY 2025 is about 30%.

• Currency expected to have a positive impact of ~1 percentage point on FY 2025 net sales and a $0.02 adverse impact on adjusted EPS.

• Tariffs expected to create a 90 basis point headwind on adjusted cost margin for 2025.